Israel - Hebräisch - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - אבקה וממס להכנת תמיסה להזרקה - follitropin alfa 150 iu; lutropin alfa 75 iu - follitropin alfa - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Israel - Hebräisch - Ministry of Health

perrigo israel agencies ltd, israel - 5-aminolevulinic acid as hydrochloride - ג'ל - 5-aminolevulinic acid as hydrochloride 78 mg/g - aminolevulinic acid

Israel - Hebräisch - Ministry of Health

padagis israel pharmaceuticals ltd, israel - diclofenac sodium - ג'ל - diclofenac sodium 3 % - diclofenac - diclofenac - for the treatment of actinic keratoses

Israel - Hebräisch - Ministry of Health

teva israel ltd - fingolimod as hydrochloride - קפסולות - fingolimod as hydrochloride 0.5 mg - fingolimod

Israel - Hebräisch - Ministry of Health

rafa laboratories ltd - fingolimod as hydrochloride - קפסולות - fingolimod as hydrochloride 0.5 mg - fingolimod

Israel - Hebräisch - Ministry of Health

discover medical devices ltd. - כלל האוכלוסיה - somnuseal device is intended for multiuse purposes to provide positive air pressure (pap) treatment to a single patient or multiple patients, as a pap interface in hospitals/clinics and/or home use provided that the user was diagnosed by a physician to require pap treatment.

Israel - Hebräisch - Ministry of Health

truemed ltd, israel - sodium phenylbutyrate - גרנולות - sodium phenylbutyrate 483 mg/g - sodium phenylbutyrate

Israel - Hebräisch - Ministry of Health

bayer israel ltd - interferon beta 1b - אבקה וממס להכנת תמיסה להזרקה - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Israel - Hebräisch - Ministry of Health

teva israel ltd - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/ml - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

Israel - Hebräisch - Ministry of Health

teva pharmaceutical industries ltd, israel - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/dose - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.